Amarantus to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
May 26 2015 - 7:05AM
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on developing therapeutic and diagnostic products
for neurological disorders and orphan indications, announced that
it will be presenting at the Fourth Annual SeeThru Equity Microcap
Investor Conference being held May 28, 2015, at Convene Grand
Central, New York, NY.
Gerald E. Commissiong, President & CEO of Amarantus, will
provide a corporate overview and an update on the clinical
development of the Company's lead therapeutic product candidate
eltoprazine for the treatment of Parkinson's disease
levodopa-induced dyskinesia (PD-LID), on Thursday, May 28, 2015, at
9:00 a.m. Eastern Time.
A live webcast of the presentation may be accessed via the News
and Events page of the Investor Relations section of the Amarantus
corporate web site under the IR Calendar at www.amarantus.com. The
webcast replay will be available approximately two hours after the
presentation ends and will be archived for 30 days.
About the Fourth Annual SeeThru Equity Microcap Investor
Conference
SeeThru Equity is the premier and unbiased provider of microcap
equity research and institutional and high net worth investor
focused conferences. Since its inception in 2011, the firm has
grown to over 125 companies under coverage and has successfully
hosted 14 investor conferences. The Fourth Annual Microcap Investor
Conference brings together over 60 presenting companies and 600
attendees. The conference offers detailed presentations, targeted
one-on-one meetings and numerous networking opportunities.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases in the areas of
neurology, psychiatry, ophthalmology and regenerative medicine.
AMBS' Therapeutics division has development rights to eltoprazine,
a Phase 2b ready small molecule indicated for Parkinson's disease
levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression,
and owns the intellectual property rights to a therapeutic protein
known as mesencephalic-astrocyte-derived neurotrophic factor (MANF)
and is developing MANF-based products as treatments for brain and
ophthalmic disorders. AMBS' Diagnostics division owns the rights to
MSPrecise®, a proprietary next-generation DNA sequencing (NGS)
assay for the identification of patients with relapsing-remitting
multiple sclerosis (RRMS) at first clinical presentation, has an
exclusive worldwide license to the Lymphocyte Proliferation test
(LymPro Test®) for Alzheimer's disease, which was developed by
Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and
owns intellectual property for the diagnosis of Parkinson's disease
(NuroPro). AMBS also owns the discovery of neurotrophic factors
(PhenoGuard™) that led to MANF's discovery.
For further information please visit www.Amarantus.com, or
connect with the Company on Facebook, LinkedIn, Twitter and
Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024